**Abstract**

The selective serotonin reuptake inhibitor, fluoxetine (FLX), is widely used to treat depression and anxiety disorders, but mechanisms underlying its antidepressant effect remain largely unknown. Previous studies that evaluated several molecular and/or electrophysiological features of the maturation stages of each neuron type have demonstrated that FLX treatment can reverse the established maturation of certain types of neurons in the hippocampus and frontal cortex (FC). However, this dematuration effect of FLX in the adult brain has not been assessed with regard to genome-wide gene expression patterns.

In this study, we compared gene expression patterns in the FLX-treated FC and hippocampus of adult mice with those of the corresponding brain regions of normal infant mice. The gene expression patterns of FLX-treated mice significantly resembled those of normal infant mice in the FC and, to a large extent, in the hippocampus. In addition, time-course analyses of the ages of infant mice used in the comparisons with FLX-treated mice indicated that the gene expression patterns of FLX-treated mice were most similar to those of the youngest infants examined (1-week-old hippocampus and 2-week-old FC).

Our results suggest that FLX treatment induces dematuration of the FC and hippocampus of adult mice with respect to genome-wide gene expression patterns. The dematuration of these brain regions might be involved in the therapeutic mechanism of FLX and/or some of its adverse effects.
